Bard gains "promising" balloon tech with Lutonix buy
This article was originally published in Clinica
CR Bard has acquired drug-eluting balloon developer Lutonix in a deal worth up to $325m, giving it access to the only DEB in US trials for peripheral arterial disease. Bard has paid $225m upfront, and will shell out a further $100m if Lutonix's device gains US FDA premarket approval (PMA). PMA submission is expected in 2014.